Payment overview · 2025
General Payments
$118.24
7 reported records · 4 companies
Healthcare provider profile · identity verified
Shelly C Bray, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · ARKADELPHIA, AR · NPI 1902824162
Verified facts
What the public records show
CMS Open Payments records show Shelly C Bray, M.D. received $118.24 in general payments during 2025 across 7 reported records.
AstraZeneca Pharmaceuticals LP accounted for 45.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Otezla.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OTEZLA as an associated drug or biological on 177267 records involving 48600 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Otezla by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 96 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 238 claims for Jardiance by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $54.00 | 45.7% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $28.70 | 24.3% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $20.10 | 17.0% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.44 | 13.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $118.24 | 7 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $30.68 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $28.70 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $28.70 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $23.32 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $20.10 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $15.44 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 96 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 238 | exact normalized | Medicare Part D |
| OTEZLA otezla |
2025 | Otezla | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | OTEZLA open payments reported associated product |
CMS Open Payments — General Payments 177267 supporting records · 48600 recipient NPIs · example record 1226871616 |
Otezla · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
96 | 20 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
238 | 48 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1005 | 260 |
| Amlodipine Besylate | Amlodipine Besylate | 722 | 183 |
| Omeprazole | Omeprazole | 412 | 109 |
| Metformin Hcl | Metformin Hcl | 393 | 94 |
| Pantoprazole Sodium | Pantoprazole Sodium | 337 | 85 |
| Levothyroxine Sodium | Levothyroxine Sodium | 334 | 81 |
| Gabapentin | Gabapentin | 326 | 59 |
| Lisinopril | Lisinopril | 326 | 91 |
| Losartan Potassium | Losartan Potassium | 323 | 81 |
| Furosemide | Furosemide | 297 | 63 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 275 | 74 |
| Hydrochlorothiazide | Hydrochlorothiazide | 271 | 63 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 252 | 34 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 248 | 66 |
| Potassium Chloride | Potassium Chloride | 240 | 64 |
| Jardiance | Empagliflozin | 238 | 48 |
| Eliquis | Apixaban | 219 | 29 |
| Meloxicam | Meloxicam | 209 | 50 |
| Sertraline Hcl | Sertraline Hcl | 186 | 45 |
| Metoprolol Tartrate | Metoprolol Tartrate | 172 | 42 |
| Tamsulosin Hcl | Tamsulosin Hcl | 171 | 36 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 161 | 46 |
| Trazodone Hcl | Trazodone Hcl | 158 | 34 |
| Escitalopram Oxalate | Escitalopram Oxalate | 152 | 34 |
| Mirtazapine | Mirtazapine | 143 | 26 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 142 | 23 |
| Allopurinol | Allopurinol | 136 | 31 |
| Bupropion Hcl Sr | Bupropion Hcl | 134 | 33 |
| Trulicity | Dulaglutide | 134 | 20 |
| Fluticasone Propionate | Fluticasone Propionate | 129 | 41 |
| Citalopram Hbr | Citalopram Hydrobromide | 121 | 28 |
| Mounjaro | Tirzepatide | 113 | 13 |
| Duloxetine Hcl | Duloxetine Hcl | 112 | 15 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 109 | 30 |
| Metoprolol Succinate | Metoprolol Succinate | 105 | 22 |
| Ozempic | Semaglutide | 101 | 24 |
| Farxiga | Dapagliflozin Propanediol | 96 | 20 |
| Prednisone | Prednisone | 95 | 57 |
| Tramadol Hcl | Tramadol Hcl | 95 | 24 |
| Quetiapine Fumarate | Quetiapine Fumarate | 93 | 17 |
| Pravastatin Sodium | Pravastatin Sodium | 91 | 25 |
| Clonazepam | Clonazepam | 89 | 12 |
| Tizanidine Hcl | Tizanidine Hcl | 88 | 16 |
| Carvedilol | Carvedilol | 82 | 15 |
| Fluoxetine Hcl | Fluoxetine Hcl | 81 | 17 |
| Tresiba Flextouch U-200 | Insulin Degludec | 78 | 16 |
| Celecoxib | Celecoxib | 72 | 15 |
| Atenolol | Atenolol | 68 | 17 |
| Ezetimibe | Ezetimibe | 68 | 16 |
| Hydralazine Hcl | Hydralazine Hcl | 68 | 18 |
| Lorazepam | Lorazepam | 67 | 13 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 66 | 21 |
| Alendronate Sodium | Alendronate Sodium | 63 | 21 |
| Diclofenac Sodium | Diclofenac Sodium | 60 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 55 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 54 | 11 |
| Metformin Hcl Er | Metformin Hcl | 53 | 14 |
| Pregabalin | Pregabalin | 52 | 11 |
| Clopidogrel | Clopidogrel Bisulfate | 51 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 48 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 47 | suppressed |
| Nifedipine Er | Nifedipine | 44 | 11 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 44 | 41 |
| Simvastatin | Simvastatin | 44 | 12 |
| Temazepam | Temazepam | 44 | suppressed |
| Famotidine | Famotidine | 41 | 12 |
| Lamotrigine | Lamotrigine | 38 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 38 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 37 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 37 | suppressed |
| Verapamil Er | Verapamil Hcl | 36 | suppressed |
| Estradiol | Estradiol | 34 | 11 |
| Levetiracetam | Levetiracetam | 34 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 34 | 14 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 33 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 33 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 32 | suppressed |
| Bupropion Xl | Bupropion Hcl | 32 | suppressed |
| Cephalexin | Cephalexin | 32 | 27 |
| Clonidine Hcl | Clonidine Hcl | 32 | suppressed |
| Finasteride | Finasteride | 32 | suppressed |
| Chlorthalidone | Chlorthalidone | 31 | suppressed |
| Nystatin | Nystatin | 31 | 20 |
| Benazepril Hcl | Benazepril Hcl | 30 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 29 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 29 | suppressed |
| Cefdinir | Cefdinir | 28 | 25 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 28 | 24 |
| Doxazosin Mesylate | Doxazosin Mesylate | 28 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 27 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 27 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 26 | suppressed |
| Azithromycin | Azithromycin | 25 | 23 |
| Ondansetron Odt | Ondansetron | 25 | 14 |
| Repatha Sureclick | Evolocumab | 25 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 25 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 24 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 24 | 14 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 24 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 24 | suppressed |
| Methotrexate | Methotrexate Sodium | 23 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 23 | suppressed |
| Spironolactone | Spironolactone | 23 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 23 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 22 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 22 | suppressed |
| Linzess | Linaclotide | 22 | suppressed |
| Topiramate | Topiramate | 21 | suppressed |
| Alprazolam | Alprazolam | 20 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 20 | 19 |
| Enalapril Maleate | Enalapril Maleate | 20 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 20 | suppressed |
| Olanzapine | Olanzapine | 20 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 19 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 19 | suppressed |
| Naproxen | Naproxen | 19 | suppressed |
| Sucralfate | Sucralfate | 19 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 18 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 18 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 18 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 18 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 17 | suppressed |
| Bumetanide | Bumetanide | 17 | suppressed |
| Memantine Hcl | Memantine Hcl | 17 | suppressed |
| Myrbetriq | Mirabegron | 17 | suppressed |
| Propafenone Hcl | Propafenone Hcl | 17 | suppressed |
| Sotalol | Sotalol Hcl | 17 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Ibuprofen | Ibuprofen | 16 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 15 | suppressed |
| Vraylar | Cariprazine Hcl | 15 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 14 | suppressed |
| Invokana | Canagliflozin | 14 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 14 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 14 | 14 |
| Tresiba Flextouch U-100 | Insulin Degludec | 14 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 13 | suppressed |
| Glipizide | Glipizide | 13 | suppressed |
| Klor-Con M20 | Potassium Chloride | 13 | suppressed |
| Prempro | Estrogen,con/M-Progest Acet | 13 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 13 | suppressed |
| Fluconazole | Fluconazole | 12 | suppressed |
| Ketoconazole | Ketoconazole | 12 | suppressed |
| Otezla | Apremilast | 12 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 12 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 12 | suppressed |
| Qulipta | Atogepant | 12 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 12 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 12 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 12 | suppressed |
| Unifine Pentips | Pen Needle, Diabetic | 12 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 12 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 11 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 11 | suppressed |
| Trospium Chloride | Trospium Chloride | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $118.24 · 7 records | AstraZeneca Pharmaceuticals LP | BREZTRI, FARXIGA, GEMTESA, JARDIANCE, OTEZLA, REPATHA | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Amgen Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error